NEURODEM study

NEURODEM study– Assessment of the iatrogenic alert indicator for nursing home patients with Alzheimer or Alzheimer-like disease

Introduction

Samir Henni, MD, MBA,ac Anne Sonnic, MD,bc Florence Delamarre Damier, MD, MBA, CMDc, Gwenaelle Feinard, Pharm D,cd Gwenaelle Veyrac, MD,ce Laure de Decker, MD, PhD,f Gilles Berrut, MD, PhD,cf Sylvie Piessard, Pharm D, PhD,cg
a Hospital Center Aimé Jallot and Francis Robert, 160 Rue du Verger, 44150 Ancenis,Franceb Pôle de Gerontologie Clinique, CHU Nantes, Hopital Bellier, 41 rue Curie, 44046 Nantes cedex 1, Francec AGREE, 8 Brairon, 44690 Château Thebaud, Franced Clinical pharmacology Department, Institute of Biology, University hospital, Nantes, Francee Clinical pharmacology Department, Institute of Biology, University hospital, Nantes, Francef Pole de Gérontologie Clinique, Hôpital Bellier, CHU de Nantes, Franceg Pharmacie Hôpital Sèvre et Loire, 44120 Vertou, Faculté de Pharmacie, Université de Nantes, 9, rue Bias BP53508, 44035 Nantes Cedex 1, Nantes, France

Neuropsychiatric symptoms (NPSs) occur in about 80% of patients during the evolution of Alzheimer’s disease and other related dementia and are often one of the reasons these people are placed in nursing homes.1 Neuroleptic drugs are often prescribed for these NPS although it is known that their efficacy is low (10-20 %).2,3

In France, in 2008, about 3 % of the elderly general population received neuroleptics compared with 18 % of those with Alzheimer’s disease and up to 27 % of those who lived in nursing homes.5 In the setting of a national plan for Alzheimer’s disease, in 2010 the French National Health Authority (in French: Haute Autorité de Santé; HAS) implemented a programme called ‘Alert and Control of the Iatrogenic risk of Neuroleptics in Alzheimer’s Disease’ (AIM-Alzheimer) to reduce the misuse of neuroleptics in patients with Alzheimer’s disease.4

Télécharger ce poster (pdf)